TIMO MYöHäNEN
Professor
Professor of Pharmacology and Drug Development
The aim of my research is to find novel drug therapies for neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases, that don't currently have curative treatment. Our long-term research topic has been PREP enzyme and targeting on it with small-molecular compounds, and we have shown that by targeting PREP we can block several toxic features in models of neurodegenerative diseases. Moreover, based on our PREP research we have found similar multitargeting drug targets, and are currently opening novel research lines.
Contact info
Organization
Faculty of Health Sciences, School of Pharmacy
timo.myohanen@uef.fi
Phone
+358 40 355 2502
Keywords
Research groups - UEF
Links
Publications
-
Cui, H.; Norrbacka, S.; Myöhänen, T.T.. 2021. Prolyl oligopeptidase acts as a link between chaperone-mediated autophagy and macroautophagy Biochemical pharmacology 2022; 197: 114899. 2021
-
Cui, Hengjing; Kilpeläinen, Tommi; Zouzoula, Lydia; Auno, Samuli; Trontti, Kalevi; Kurvonen, Sampo; Norrbacka, Susanna; Hovatta, Iiris; Jensen, Poul Henning; Myöhänen, Timo T.. 2021. Prolyl oligopeptidase inhibition reduces alpha-synuclein aggregation in a cellular model of multiple system atrophy Journal of cellular and molecular medicine 25 20: 9634-9646. 2021
-
Eteläinen, T; Kulmala, V; Svarcbahs, R; Jäntti, M; Myohänen, T T. 2021. Prolyl oligopeptidase inhibition reduces oxidative stress via reducing NADPH oxidase activity by activating protein phosphatase 2A Free radical biology and medicine 169: 14-23. 2021
-
Hellinen, Laura; Koskela, Ali; Vattulainen, Elina; Liukkonen, Mikko; Wegler, Christine; Treyer, Andrea; Handin, Niklas; Svensson, Richard; Myöhänen, Timo; Poso, Antti; Kaarniranta, Kai; Artursson, Per; Urtti, Arto. 2021. Inhibition of prolyl oligopeptidase: A promising pathway to prevent the progression of age-related macular degeneration Biomedicine and pharmacotherapy 2022; 146: 112501. 2021
-
Myöhänen, Timo T; Mertens, Freke; Norrbacka, Susanna; Cui, Hengjing. 2021. Deletion or inhibition of prolyl oligopeptidase blocks lithium-induced phosphorylation of GSK3b and Akt by activation of protein phosphatase 2A Basic and clinical pharmacology and toxicology 129 4: 287-296. 2021
-
Pätsi, Henri T.; Kilpeläinen, Tommi P.; Auno, Samuli; Dillemuth, Pyry M. J.; Arja, Khaled; Lahtela-Kakkonen, Maija K.; Myöhänen, Timo T.; Wallén, Erik A. A.. 2021. 2-Imidazole as a Substitute for the Electrophilic Group Gives Highly Potent Prolyl Oligopeptidase Inhibitors Acs medicinal chemistry letters 12 10: 1578-1584. 2021
-
Zuo Yiqin, Chun Bongkwon, Potthoff Sebastian A, Kazi Naj, Brolin Tyler J, Orhan Diclehan, Yang Hai-Chun, Ma Li-Jun, Kon Valentina, Myöhänen Timo, Rhaleb Nour-Eddine, Carretero Oscar A, Fogo Agnes B. 2013. Thymosin β 4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis Kidney international 84: 1166-1175. 2013
-
Myöhänen TT, Garcia-Horsman JA, Tenorio-Laranga J, Männistö PT. 2009. Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity Journal of histochemistry and cytochemistry 57 9: 831-848. 2009
-
Myöhänen TT, Kääriäinen TM, Jalkanen AJ, Piltonen M, Männistö PT. 2009. Localization of prolyl oligopeptidase in the thalamic and cortical projection neurons: A retrograde neurotracing study in the rat brain Neuroscience letters 450: 201-205. 2009
-
Myöhänen T (ed.) . 2008. Distribution of Prolyl Oligopeptidase and its Colocalizations with Neurotransmitters and Substrates in Mammalian Tissues. Kuopion yliopiston julkaisuja A. Farmaseuttiset tieteet. 2008